Trial Profile
A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2010/2011 in People Aged 18 Years or Above.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 02 Jul 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.